Trial Profile

A Phase 3 study of REM-001 in cutaneous metastatic breast cancer (CMBC) patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rostaporfin (Primary)
Indications Advanced breast cancer
Focus Registrational; Therapeutic Use
Sponsors Kintara Therapeutics; TuHURA Biosciences

Most Recent Events

17 Oct 2024 According to a TuHURA Biosciences media release, company announced merger with Kintara Therapeutics, Inc. and the combined company will operate under the name "TuHURA Biosciences, Inc.''
16 Feb 2024 New trial record
12 Feb 2024 According to a Kintara Therapeutics media release, the open label 15-patient study in CMBC patients is evaluating REM-001, a second-generation photodynamic therapy (PDT) photosensitizer agent, and is designed to test the 0.8 mg dose as well as optimize the study design in advance of a Phase 3 trial initiation.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com